-+ 0.00%
-+ 0.00%
-+ 0.00%

Decoy Therapeutics says next-generation D-MAVs show in vitro activity against Ebola Zaire, Marburg viruses

PUBT·09/22/2026 11:33:31
Decoy Therapeutics says next-generation D-MAVs show in vitro activity against Ebola Zaire, Marburg viruses
  • Decoy Therapeutics reported low-micromolar in vitro potency for a de novo filovirus fusion inhibitor against wild-type Ebola Zaire.
  • The candidate showed cross-family activity against Marburg virus in cell-based assays, supporting a planned single pan-filovirus prophylactic program.
  • Development strategy shifted toward an FDA Animal Rule pathway, pairing animal efficacy studies with human safety and pharmacokinetics.
  • Program funding focus moved to non-dilutive grants and biodefense partnerships, targeting potential Priority Review Voucher monetization of USD 100-180 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609220730PR_NEWS_USPR_____NE53528) on September 22, 2026, and is solely responsible for the information contained therein.